Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer
Articles > Article · 2017
Authors: Luis G. Paz-Ares, Maurice PÉROL, Tudor-Eliade CİULEANU, Ruben Dario KOWALYSZYN, Martin RECK, Conrad R. Lewanski, Konstantinos SYRİGOS, Oscar ARRİETA, Kumar PRABHASH, Keunchil PARK, Joanna PİKİEL, Tuncay GÖKSEL, Pablo LEE, Anna ZİMMERMANN, Gebra Cuyun CARTER, Ekaterine ALEXANDRİS, Edward B. Garon
Lung Cancer, Journal Indexed in SCI Expanded, International, WoS, 2017, vol 112, pp 126-133
DOI: 10.1016/j.lungcan.2017.05.021
Summary
Objectives: Ramucirumab, a recombinant human immunoglobulin G1 monoclonal antibody inhibiting vascular endothelial growth factor receptor-2, increased overall survival (OS) combined with docetaxel versus docetaxel alone in non-small cell lung cancer (NSCLC) in the REVEL trial. Pre-specified exploratory analysis examined efficacy and safety by histology.